In a recent blog, I discussed the change in nomenclature for the conditions formerly known as Neurofibromatosis type 2 (NF2) and schwannomatosis. This change was based on the results of an ...
IVDR: where are we now in molecular testing? How IVDR implementation is progressing in molecular biology laboratories in different European countries IVDR, the new EU legislation for in-vitro ...
The pharmacogenomics landscape is evolving from a niche scientific pursuit to a cornerstone of value-based healthcare,” said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback